The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study – A Prospective Cohort Study
Basil Abdin, Eman Abuqweider, Imad Alhaddad, Remin Shabaneh, Ghayda’ Bader, Taima Bader, Mohammad Abu-Shaban, Qais Salah, Ayman Hammoudeh · 2025
Read The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study – A Prospective Cohort Study by Basil Abdin, Eman Abuqweider, Imad Alhaddad, Remin Shabaneh, Ghayda’ Bader, Taima Bader, Mohammad Abu-Shaban, Qais Salah, Ayman Hammoudeh (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750794.txt.
Description
A racing, irregular heartbeat plus a pile of other diseases is a grim mix, and Basil Abdin and co-authors measure it in Jordan's national registry in this 2025 study. Over 1,900 patients with atrial fibrillation were followed for a year. Those with three or more extra conditions made up about 43 percent of the group.
The multi-disease group landed in hospital more and died at over double the rate, 21 percent against 9.5 percent. Heart-related death also ran higher. High blood pressure stood out as the deadliest companion. Nearly all patients took blood thinners under modern practice. The authors say Middle Eastern data on this mix were scarce, and their numbers argue for treating the whole patient, not just the rhythm.
Catalog record
| CREATOR | Basil Abdin, Eman Abuqweider, Imad Alhaddad, Remin Shabaneh, Ghayda’ Bader, Taima Bader, Mohammad Abu-Shaban, Qais Salah, Ayman Hammoudeh |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |